234080 — JW Life Science Income Statement
0.000.00%
Last trade - 00:00
- KR₩183bn
- KR₩197bn
- KR₩207bn
- 82
- 81
- 66
- 92
2019 December 31st | R2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 170,221 | 183,521 | 169,817 | 188,931 | 206,860 |
Cost of Revenue | |||||
Gross Profit | 48,605 | 59,497 | 49,157 | 48,121 | 52,393 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 140,472 | 151,253 | 141,315 | 161,842 | 176,009 |
Operating Profit | 29,749 | 32,268 | 28,502 | 27,089 | 30,851 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 28,331 | 22,740 | 18,287 | 20,782 | 33,708 |
Provision for Income Taxes | |||||
Net Income After Taxes | 21,938 | 17,300 | 12,914 | 14,961 | 28,144 |
Net Income Before Extraordinary Items | |||||
Net Income | 21,938 | 17,300 | 12,914 | 14,961 | 28,144 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Dilution Adjustment | |||||
Diluted Net Income | 21,938 | 17,300 | 12,914 | 14,961 | 28,144 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 1,385 | 1,438 | 841 | 967 | 1,827 |
Dividends per Share |